Skip to main content
Premium Trial:

Request an Annual Quote

Susan Siegel, Stephen Fodor, Thane Kreiner, Hilary Malone, Mark Stevenson, William Murray, Leonard Klevan, Jorge Garces, Cindy Ahn, Leroy Hood, Kenneth Conway, Arthur Holden and more



Susan Siegel has resigned as president of Affymetrix, the company said last week. Siegel will be "transitioning from her current role" and will represent the company as president emeritus. Affy said she will stay on as an advisor and continue to report to Chairman and CEO Stephen Fodor.

Thane Kreiner, vice president of corporate affairs, has been named senior vice president of marketing and sales.

It was not immediately clear why Siegel stepped down, whether the resignation takes immediate effect, or whether Kreiner's role will overlap her duties. Also not clear is whether Affy has begun looking for a replacement.

Siegel joined Affymetrix in 1998 as senior vice president of sales and marketing — the same title to which Kreiner was now promoted. Affy named her president in 1999 and appointed her to the board two years later.

Wyeth Pharmaceuticals this week said it has appointed Hilary Malone senior vice president of global regulatory affairs. She joined Wyeth from AstraZeneca, where she served as vice president of European regulatory affairs since 2001. She has also worked in regulatory affairs at GlaxoSmithKline, the company said.

Applied Biosystems announced last week that Mark Stevenson has been appointed president of the firm's molecular biology division. He previously served as president of the firm's applied markets division. Stevenson succeeds William Murray, who has resigned due to personal reasons.

ABI also announced that Leonard Klevan has replaced Stevenson as president of the applied markets division. Klevan joined ABI earlier this year as vice president of R&D for applied markets. Before joining ABI, he was CEO of ReliaGene Technologies. He also is a former president and CEO of MiraiBio, a subsidiary of Hitachi Software Engineering, and had managed technology acquisitions and business development at Life Technologies, which was acquired by Invitrogen in 2000.

Third Wave Technologies has made two new appointments to its senior management team: Jorge Garces has been appointed vice president of product and platform development, and Cindy Ahn has been appointed vice president and general counsel.

Garces joined Third Wave from Genzyme Genetics in October 2005 as executive director of clinical development. He served as director of molecular research and development at Genzyme Genetics, where he oversaw the technology and product development activities of laboratory staff in New York, Los Angeles, and Westborough, Mass. He earned his BS in biology from Brooklyn College and his PhD in cell and molecular biology from the City University of New York.

Ahn joins Third Wave from the Kirkland & Ellis law firm, where she was a partner and "key" member of the team that successfully litigated Third Wave's patent infringement suit against Stratagene. That suit resulted in a $20.1-million award to Third Wave. Ahn has a BS in biology from the University of Illinois and her law degree from American University's Washington College of Law.

Leroy Hood, president and co-founder of Institute for Systems Biology, and Josh LaBaer, founder and director of the Institute of Proteomics at Harvard Medical School, have joined Lumera's scientific advisory board.

Ciphergen Biosystems has appointed Kenneth Conway to its board. Conway founded Millennium Predictive Medicine and Vitivity, both of which focus on the predictive medicine arena. He holds a BS from Rutgers University and attended the Executive Program at Dartmouth College's Dartmouth Institute, Tuck School of Business Administration.

Illumina has appointed Arthur Holden as senior vice president of corporate and market development, a new position. Holden will be charged with "developing relationships and partnerships with key customers in the pharmaceutical industry, large-scale research consortia and governmental bodies including the NIH and the US Food and Drug Administration," Illumina said. He will also serve as Illumina's representative on the Personalized Medicine Coalition and also help lead content development strategies for the company's products, "particularly those being developed for molecular diagnostics and clinical applications."

Holden was most recently chairman, CEO, and principal founder of First Genetic Trust. He is chairman of the Pharmaceutical Biomedical Research Consortium and the DMD Translational Research Consortium. Holden was formerly CEO of the SNP Consortium and CEO and a director of Celsis International, an industrial biotechnology company. He has an MBA from the J.L. Kellogg Graduate School of Management and a BS from Union College.

Alnylam Pharmaceuticals President and Chief Executive Officer John Maraganore and Invitrogen CEO Greg Lucier have been appointed to the board of directors of the Biotechnology Industry Organization. They will serve three-year terms.

Exagen Diagnostics has hired Katharine Hawes as director of manufacturing, and Catherine Michael as director of customer care. Hawes will be based in Exagen's Albuquerque, NM, office and Michael will be based in Austin, Texas. Both are new positions.

Hawes comes to Exagen from Bioarray Solutions in Warren, NJ, where she was retained as a consultant to establish current good manufacturing practice and associated infrastructure.

Michael, before joining Exagen, was head of client services at Austin-based Esoterix, where she established two centralized client services call centers.

Harry Glorikian, partner and management consultant of TSG Partners' Boston office, has been asked by the Charles Stark Draper Laboratory to become a member of its biomedical advisory board.

Glorikian currently leads the New England office of TSG Partners, including the management of consulting teams, new business development, and intellectual capital development.

New Releases

CombiMatrix Molecular Diagnostics last week launched its comparative genomic hybridization array for detecting genomic copy number variations in pre- and post-natal analysis, the company said in a statement. The array is intended to detect genomic copy number variations associated with constitutional chromosomal imbalances and "more than 40" genetic diseases and syndromes, the company said. The array is shipping to Europe, and will require FDA clearance before it can be sold in the United States for anything other than research use, CombiMatrix said.

Nanogen this week launched a set of probes and primers for detecting Epstein-Barr virus using real-time PCR based methods. EBV is the cause of infectious mononucleosis and several lymphoproliferative disorders.

SoftGenetics has launched an updated version of its Mutation Surveyor software, outfitting it with a methylation-detection function to automate DNA sequence analysis for these epigenetic modifications.

Filed under

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.